merck-keytruda

NICE recommends MSD’s Keytruda for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma

pharmafile | October 22, 2020 | News story | Sales and Marketing |  MSD, NCIE, NHS, keytruda 

NICE has moved to recommend the use of MSD’s blockbuster immunotherapy drug Keytruda (pembrolizumab) as a monotherapy in the treatment of previously untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC).

NICE estimates that around 950 patients in England and Wales with PD-L1-mutated tumours will be eligible to receive the therapy via the NHS based on this new decision.

Clinical trial data reviewed by NICE demonstrated that Keytruda was at least as effective in both standard interventions for head and neck cancer. Treatment approach is different depending on where the patient’s cancer originated: in cancer originating inside the mouth, Keytruda was at least as effective as the standard treatment of cetuximab, platinum chemotherapy and 5-fluorouracil (5-FU), and is delivered at a lower overall cost.

In cancer originating outside of the mouth, Keytruda was shown to be more effective than the standard treatment of platinum chemotherapy in addition to 5-FU. The cost of Keytruda was higher, but NICE judged this to be a cost-effective use of resources given the added benefit – it recommended that Keytruda be used only as a monotherapy in these indications and not in combination.

Advertisement

Matt Fellows

Related Content

NHS expands community ear and hearing pathway across 10 ICBs

A new NHS ear and hearing health pathway supported by TympaHealth has been rolled out …

PlaqueTec coronary disease trial reaches 100 patients across eight NHS centres

PlaqueTec’s BIOPATTERN clinical trial has recruited its 100th patient and expanded to eight NHS specialist …

“That gap between innovation and delivery was what stood out to me most”

Pharmafile chats with Camunda’s Natosha McNeal about the vital role of delivery, onboarding AI and …

The Gateway to Local Adoption Series

Latest content